Skip to Content
Merck
CN

202673

Arsenic(III) oxide

99.995% trace metals basis, powder

Synonym(s):

ATO, Diarsenic trioxide;, Arsenic trioxide, Arsenous acid

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
As2O3
CAS Number:
1327-53-3
Molecular Weight:
197.84
UNSPSC Code:
12161600
eCl@ss:
38080102
PubChem Substance ID:
24852110
NACRES:
NA.22
EC Number:
215-481-4
MDL number:
MFCD00003433

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Arsenic(III) oxide, 99.995% trace metals basis

SMILES string

O=[As]O[As]=O

InChI

1S/As2O3/c3-1-5-2-4

InChI key

IKWTVSLWAPBBKU-UHFFFAOYSA-N

assay

99.995% trace metals basis

form

powder

reaction suitability

core: arsenic
reagent type: catalyst

Quality Level

200

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application


  • Electrochemical detection applications: A study on La-based perovskites incorporated with functionalized carbon nanofibers highlights the use of arsenic trioxide for the electrochemical detection of roxarsone in water and food samples, providing a method to improve safety and environmental monitoring (John Felix MA et al., 2024).

  • Antiproliferative effects in cancer research: Research demonstrates the inhibitory effects of arsenic trioxide, combined with metformin, on KG1a cell proliferation, suggesting its potential utility in developing antineoplastic strategies (Huang-Li WH et al., 2024).

  • Environmental remediation: A review on manganese oxide-based materials for arsenic removal discusses the application of arsenic trioxide in environmental remediation, focusing on the effectiveness and advancements in arsenic decontamination technologies (Younas M et al., 2024).

General description

Arsenic(III) oxide (ATO) is an inorganic form of arsenic that is used as a therapeutic compound for treating patients with acute promyelocytic leukemia (APL). Many drug-delivery methods are currently being developed using nanotechnology to overcome its poor bioavailability due to rapid clearance from blood.

signalword

Danger

Hazard Classifications

Acute Tox. 2 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1A - Eye Dam. 1 - Skin Corr. 1B - STOT RE 1

target_organs

Respiratory system,Cardio-vascular system,Gastrointestinal tract

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Faceshields, Gloves, type P3 (EN 143) respirator cartridges

Regulatory Information

监管及禁止进口产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
MKCX7641
MKCS6209
MKCQ5308
MKCQ0318
MKCP5657

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A facile route to core?shell nanoparticulate formation of arsenic trioxide for effective solid tumor treatment.
Zhang Z, et al.
Nanoscale, 8(7), 4373-4380 (2016)
Silica nanovehicles endow arsenic trioxide with an ability to effectively treat cancer cells and solid tumors.
Zhao Z, et al.
Journal of Materials Chemistry, 2(37), 6313-6323 (2014)
Recent advances in arsenic trioxide encapsulated nanoparticles as drug delivery agents to solid cancers.
Akhtar A, et al.
Journal of biomedical research, 31(3), 177-177 (2017)
Ruoshi Xu et al.
Bone research, 6, 33-33 (2018-11-28)
How osteoblast cells are induced is a central question for understanding skeletal formation. Abnormal osteoblast differentiation leads to a broad range of devastating craniofacial diseases. Here we have investigated intramembranous ossification during cranial bone development in mouse models of skeletal
Liangchun Hao et al.
Journal of pediatric hematology/oncology, 35(2), e67-e70 (2013-02-16)
The aim of this study was to investigate the hepatotoxicity induced by arsenic trioxide (As2O3) at a therapeutic dose for pediatric acute promyelocytic leukemia (APL). A total of APL patients received As2O3 treatment by IV drip. Hepatotoxicity was monitored based
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service